Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TAF1 | P21675 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | PTPRE | P23469 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25079005 | 1.00 | TNF (0.39) | TNFRIPK1TYRAHRBRD4 | |
| SCHEMBL18966966 | 0.78 | TNF (0.59) | TNFRIPK1AHRBRD4TAF1 | |
| SCHEMBL1875458 | 0.77 | TNF (0.42) | TNFRIPK1TYRAHRBRD4 | |
| SCHEMBL6097464 | 0.77 | TNF (0.42) | TNFRIPK1AHRBRD4TAF1 | |
| SCHEMBL29713816 | 0.77 | TNF (0.42) | TNFRIPK1AHRBRD4TAF1 | |
| SCHEMBL5580913 | 0.76 | MAPT (0.52) | TNFRIPK1AHRBRD4TAF1 | |
| SCHEMBL16091101 | 0.76 | TNF (0.50) | TNFRIPK1AHRBRD4TAF1 | |
| SCHEMBL24373440 | 0.74 | TNF (0.39) | TNFRIPK1AHRBRD4TAF1 | |
| SCHEMBL24953856 | 0.74 | TNF (0.39) | TNFRIPK1AHRBRD4TAF1 | |
| SCHEMBL29361387 | 0.74 | TNF (0.39) | TNFRIPK1AHRBRD4TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630122-A1 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | Aptose Biosciences Inc. (CA) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024124199-A9 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | APTOSE BIOSCIENCES INC. (CA) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024124199-A1 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | APTOSE BIOSCIENCES INC. (CA) | 2024-06-13 | — | — | WO | disclosed |
| US-11292786-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292786-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | TNF 1997/4885RIPK1 2736/4885TYR 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.